Brought to you by 
Novartis options rights to Quark's QPI1002
06 Nov 2017
Executive Summary
Quark Pharmaceuticals Inc. (RNAi therapeutics) has granted Novartis AG an option for the exclusive development and marketing rights to QPI1002, a Phase II siRNA drug candidate for acute kidney injury in cardiac surgery patients and as a prophylaxis for delayed graft function (DGF) in patients undergoing kidney transplants from deceased organ donors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis options rights to Quark's QPI1002
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice